Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This clinical trial explores the safety, efficacy, and effects on functional imaging of cG250
monoclonal antibody (mAb) administered intravenously weekly in combination with daily oral
sunitinib, in patients with advanced renal cell carcinoma.